Open AccessTargeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours
Author(s) -
Tatsuhiro Ishida,
Tsuyoshi Takahashi,
Yukinori Kurokawa,
Toshirou Nishida,
Seiichi Hirota,
Satoshi Serada,
Minoru Fujimoto,
Tetsuji Naka,
Ryugo Teranishi,
Takuro Saito,
Kotaro Yamashita,
Koji Tanaka,
Keiji Yamamoto,
Tomoki Makino,
Makoto Yamasaki,
Kiyokazu Nakajima,
Hidetoshi Eguchi,
Yuichiro Doki
Publication year - 2021
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-021-01566-9
Subject(s) - gefitinib , imatinib , cancer research , medicine , cancer cell , pharmacology , gist , cancer , stromal cell , biology , epidermal growth factor receptor , myeloid leukemia
Despite the effectiveness of tyrosine kinase inhibitors (TKI), gastrointestinal stromal tumours (GIST) develop after the withdrawal of TKI. Based on previous studies, a subpopulation of drug-tolerant cells called "persister cells" may be responsible for the recurrence and have thus, gained attention as a novel target in cancer therapy.